RecruitingNCT07176260

Exploring Blood Cell Function and Oxidative Stress to Improve Diagnosis and Treatment in Pre-Capillary Pulmonary Hypertension

Diagnostic and Prognostic Significance of Circulating Oxidative Stress and Blood Cell Mitochondrial Respiration in Pre-Capillary Pulmonary Hypertension


Sponsor

University Hospital, Strasbourg, France

Enrollment

120 participants

Start Date

Sep 1, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

This study aims to understand how blood cell (including peripheral blood mononuclear cells ((PBMCs) or platelets) function and oxidative stress can help physicians detect and predict the course of pre-capillary pulmonary hypertension. We hypothesize that changes in the mitochondrial function of blood cells and oxidative stress may be early markers of disease progression and severity. The study will also explore how these blood markers relate to routine clinical and heart function measurements, such as echocardiography, right heart catheterization, 6-minute walk tests, and functional status, to see if they can help monitor patients over time and guide personalized care. This is a non-interventional study. Blood samples will be collected during routine visits planned for diagnosis and follow-up. The study will include 120 patients diagnosed with pre-capillary pulmonary hypertension, who will be followed for 3 years. Blood samples will be taken up to three times per year to measure mainly oxidative stress and mitochondrial function in blood cells. These measurements will be compared with clinical tests to see if they can help predict the course of the disease.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating blood cell function and oxidative stress (cellular damage from unstable molecules) in people with pre-capillary pulmonary hypertension — a serious condition where the blood pressure in the lungs is dangerously elevated. Researchers hope to identify better tools for diagnosis and monitoring. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with pre-capillary pulmonary hypertension confirmed by right heart catheterization — this includes Group 1 (PAH), Group 3 (PH with lung disease), or Group 4 (chronic blood clot-related PH) - You are already scheduled for routine follow-up care or a right heart catheterization at the study center - You are willing and able to provide informed consent **You may NOT be eligible if...** - You have a different type of pulmonary hypertension (e.g., Group 2, caused by left heart disease) - You are unable to attend scheduled follow-up visits - You are unwilling to provide consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERPatients with pre-Capillary pulmonary hypertension

Patients will be followed for 3 years with routine clinical, hemodynamic, and laboratory assessments. Blood samples for oxidative stress and mitochondrial function analyses will be collected during scheduled follow-up visits or catheterization procedures. No intervention beyond standard care will be performed.


Locations(1)

Hôpitaux Universitaires de Strasbourg - Service Physiologie explorations fonctionnelles

Strasbourg, Bas-Rhin, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07176260